Drug-induced Liver Injury 1986;104:399–404.
24. Schmidt LE, et al., Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity, Hepatology, 2002;35:876–82.
25. Tarantino G, et al., A prospective study of acute drug- induced liver injury in patients suffering from non-alcoholic fatty liver disease, Hepatol Res, 2007;37:410–5.
26. Gupta NK, et al., The use of potentially hepatotoxic drugs in patients with liver disease, Aliment Pharmacol Ther, 2008;28:1021–41.
27. Tarantino G, et al., Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol, 2009;15:2817–33.
28. Huang YS, Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug- induced liver injury, Expert Opin Drug Metab Toxicol, 2007;3:1–8.
29. Daly AK, et al., Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes, Gastroenterology, 2007;132:272–81.
30. O’Donohue J, et al., Co-amoxiclav jaundice: clinical and histological features and HLA class II association, Gut, 2000;47:717–20.
31. Andrade RJ, et al., HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease, Hepatology, 2004;39:1603–12.
32. Daly AK, et al., HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 2009;41:816–9.
33. Zafrani ES, et al., Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases, Dig Dis Sci, 1979;24:385–96.
34. Mohi-ud-din R, et al., Drug- and chemical-induced cholestasis, Clin Liver Dis, 2004;8:95–132, vii.
35. Bjornsson E, et al., The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury, Aliment Pharmacol Ther, 2007;25:1411–21.
36. Tajiri K, et al., Practical guidelines for diagnosis and early management of drug-induced liver injury, World J Gastroenterol, 2008;14:6774–85.
37. Benichou C, Criteria of drug-induced liver disorders. Report of an international consensus meeting, J Hepatol, 1990;11:272–6.
38. Danan G, et al., Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug- induced liver injuries, J Clin Epidemiol, 1993;46:1323–30.
39. Maria VA, et al., Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis, Hepatology, 1997;26:664–9.
40. Aithal GP, et al., Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions, J Hepatol, 2000;33:949–52.
41. Lucena MI, et al., Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 2001;33:123–30.
42. Hoofnagle JH, Drug-induced liver injury network (DILIN), Hepatology, 2004;40:773.
43. Chalasani N, et al., Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 2008;135:1924–34, 1934 e1–4.
44. Fontana RJ, et al., Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 2009;32:55–68.
45. O’Grady JG, et al., Early indicators of prognosis in fulminant hepatic failure, Gastroenterology, 1989;97:439–45.
46. Schmidt LE, et al., MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury, Hepatology, 2007;45:789–96.
47. Yamagishi Y, et al., A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis, J Gastroenterol, 2009;44:615–23.
48. Slattery JT, et al., The complex interaction between ethanol and acetaminophen, Clin Pharmacol Ther, 1996;60:241–6.
49. Rumack BH, et al., Acetaminophen poisoning and toxicity, Pediatrics, 1975;55:871–6.
50. Kenna JG, Immunoallergic drug-induced hepatitis: lessons from halothane, J Hepatol, 1997;26(Suppl 1):5–12.
51. Lo SK, et al., Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation, Eur J Gastroenterol Hepatol, 1998;10:635–9.
52. Njoku D, et al., Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury, Anesth Analg, 1997;84:173–8.
53. Eliasson E, et al., Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis, Mol Pharmacol, 1996;50:573–82.
54. Bourdi M, et al., Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis, Chem Res Toxicol, 1996;9:1159–66.
55. Manov I, et al., Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects, Acta Pharmacol Sin, 2006;27:259–72.
56. Aithal GP, et al., Nonsteroidal anti-inflammatory drug- induced hepatotoxicity, Clin Liver Dis, 2007;11:563–75, vi–vii.
57. Shen S, et al., Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac, Chem Res Toxicol, 1999;12:214–22.
58. Kenny JR, et al., Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac, J Med Chem, 2004;47:2816–25.
59. Laine L, et al., How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial, Am J Gastroenterol, 2009;104:356–62.
60. Sanchez-Matienzo D, et al., Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports, Clin Ther, 2006;28:1123–32.
61. Walker SL, et al., Nimesulide associated fulminant hepatic failure, Pharmacoepidemiol Drug Saf, 2008;17:1108–12.
62. Wood LJ, et al., Sulindac hepatotoxicity: effects of acute and chronic exposure, Aust N Z J Med, 1985;15:397–401.
63. Tarazi EM, et al., Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration, Gastroenterology, 1993;104:569–74.
64. Sgro C, et al., Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 2002;36:451–5.
65. Andrade RJ, et al., Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10- year period, Gastroenterology, 2005;129:512–21.
66. Ohkawa K, et al., Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients, Clin Pharmacol Ther, 2002;72:220–6.
67. Sharifzadeh M, et al., Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment, Pharmacol Res, 2005;51:353–8.
68. Fernandez-Villar A, et al., The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity, Int J Tuberc Lung Dis, 2004;8:1499–505.
69. Tostmann A, et al., Antituberculosis drug-induced hepatotoxicity: concise up-to-date review, J Gastroenterol Hepatol, 2008;23:192–202.
70. Saukkonen JJ, et al., An official ATS statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 2006;174:935–52.
71. Sarma GR, et al., Venkatesan P, Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin, Am Rev Respir Dis, 1986;133:1072–5.
72. Steele MA, et al., Toxic hepatitis with isoniazid and rifampin. A meta-analysis, Chest, 1991;99:465–71.
73. Idilman R, et al., Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy, Liver Transpl, 2006;12:1427–30.
74. Polesky A, et al., Rifampin preventive therapy for tuberculosis in Boston’s homeless, Am J Respir Crit Care Med, 1996;154:1473–7.
75. Villarino ME, et al., Rifampin preventive therapy for
tuberculosis infection: experience with 157 adolescents, Am J Respir Crit Care Med, 1997;155:1735–8.
76. Fountain FF, et al., Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection, Am J Med Sci, 2009;337:317–20.
77. Byrne JA, et al., The human bile salt export pump: characterization of substrate specificity and identification of inhibitors, Gastroenterology, 2002;123:1649–58.
78. Chang KC, et al., Hepatotoxicity of pyrazinamide: cohort and case-control analyses, Am J Respir Crit Care Med, 2008;177:1391–6.
79. Jasmer RM, et al., Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial, Ann Intern Med, 2002;137:640–7.
80. Younossian AB, et al., High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis, Eur Respir J, 2005;26:462–4.
81. Papastavros T, et al., Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis, CMAJ, 2002;167:131–6.
82. Ridzon R, et al., Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin, Clin Infect Dis, 1997;24:1264–5.
83. Garcia Rodriguez LA, et al., Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid, Arch Intern Med, 1996;156:1327–32.
84. Lucena MI, et al., Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain, Hepatology, 2006;44:850–6.
85. Fontana RJ, et al., Acute liver failure due to amoxicillin and amoxicillin/clavulanate, Dig Dis Sci, 2005;50:1785–90.
86. Hautekeete ML, Hepatotoxicity of antibiotics, Acta Gastroenterol Belg, 1995;58:290–6.
87. Barrio J, et al., [Hepatotoxicity caused by cloxacillin], Rev Esp Enferm Dig, 1997;89:559–60.
88. Presti ME, et al., Nafcillin-associated hepatotoxicity. Report of a case and review of the literature, Dig Dis Sci, 1996;41:180–4.
89. Andrews E, et al., Flucloxacillin-induced liver injury, Toxicology, 2008;254:158–63.
90. Derby LE, et al., Erythromycin-associated cholestatic hepatitis, Med J Aust, 1993;158:600–2.
91. Braun P, Hepatotoxicity of erythromycin, J Infect Dis, 1969;119:300–6.
92. Tonder M, et al., Sulfonamide-induced chronic liver disease, Scand J Gastroenterol, 1974;9:93–6.
93. Kowdley KV, et al., Prolonged cholestasis due to trimethoprim sulfamethoxazole, Gastroenterology, 1992;102:2148–50.
94. Kouklakis G, et al., Cholestatic hepatitis with severe systemic reactions induced by trimethoprim- sulfamethoxazole, Ann Hepatol, 2007;6:63–5.
95. Zaman F, et al., Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure, Clin Transplant, 2003;17:461–4.
96. Iwarson S, et al., Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases, Scand J Gastroenterol, 1979;14:497–502.
97. Stricker BH, et al., Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases, Hepatology, 1988;8:599–606.
98. Garcia Rodriguez LA, et al., A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs, Br J Clin Pharmacol, 1999;48:847–52.
99. Stricker BH, et al., Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases, J Hepatol, 1986;3:399–406.
ien RN, et al., Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study, Hepatology, 1997;25:103–7.
ndor JA, et al., Ketoconazole-induced liver damage, Medicina (B Aires), 1998;58:277–81.
rveze Z, et al., et al., Terbinafine-induced hepatic failure requiring liver transplantation, Liver Transpl, 2007;13:162–4.
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92
| Page 93
| Page 94
| Page 95
| Page 96
| Page 97
| Page 98
| Page 99
| Page 100